Immuno-nutrition Supplementation in Haemodialysis

Status Completed

Clinical Trial Summary

The purpose of this pilot study is to test if an "immuno-nutrition" supplement can decrease inflammation in people on haemodialysis. This immuno-nutrition supplement is high in calories and protein like other common nutritional supplements, but also contains a unique combination of ingredients that have been shown to reduce inflammation (a problem which is caused by the body's defence [immune] system communicating that something is wrong) and improve the immune system in people with cancer. The research team hopes that this small study will help with gaining a good understanding of the effect of immuno-nutrition on inflammation in people on haemodialysis, which will guide and allow the research team to do a larger research study in the future.

Clinical Trial Description

Participants will be asked to take one sachet of the immuno-nutrition supplement each day for 6 weeks. The renal dietitian on the research team will provide participants with detailed oral advice on how and when to take the immuno-nutrition supplement. Participants will need to complete 3-day food diaries at the beginning, mid-way point and end of the study. The research team will measure weight, height, handgrip strength (a measure of muscle strength), body's composition of fat and muscle using a specialist scale, and skin autofluorescence levels (a measure of toxins called advanced glycation end-products). The research team will collect the results of routine blood tests. The research team will also collect and store blood samples taken before and after a haemodialysis session to measure some molecules that indicate inflammation. All of these measurements and samples will be taken at the start of the study, and after 6 weeks of taking the immuno-nutrition supplement. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05700851
Study type	Interventional
Source	University of Nottingham
Contact
Status	Completed
Phase	N/A
Start date	September 27, 2022
Completion date	December 9, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT02616627` - Association Between DXA Results and the Complications, Clinical Courses and Outcomes in Chronic Dialysis Patients
Completed	`NCT01464190` - A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients	Phase 3
Recruiting	`NCT06040281` - Smart and Fit for Kidney Transplantation	N/A
Active, not recruiting	`NCT03535922` - Evaluation of Routinely Measured Patient-reported Outcomes in Hemodialysis Care	N/A
Completed	`NCT04622709` - Pilot Study of Loop Diuretics Among Individuals Receiving Hemodialysis	Phase 2
Completed	`NCT04585607` - Potential Benefits of Expanded Hemodialysis in Prevention of Sarcopenia	Phase 4
Completed	`NCT03182699` - Effect of Etelcalcetide on Cardiac Hypertrophy in Hemodialysis Patients	Phase 4
Completed	`NCT03942744` - The Effect of High-flux Hemodialysis and On-line Hemodiafiltration on Endothelial Function.	N/A
Completed	`NCT04549597` - Study to Evaluate the Use of Tenapanor as Core Therapy in the Treatment of Hyperphosphatemia	Phase 4
Recruiting	`NCT04659525` - Evolocumab Plus Ezetimibe in Haemodialized Statin-intolerant Patients With Hypercholesterolemia	Phase 4
Completed	`NCT04125537` - Pathways Project: Kidney Supportive Care
Recruiting	`NCT03347773` - Oral Nutritional Supplement Intervention Among Hemodialysis Patients With Sarcopenic Obesity	N/A
Recruiting	`NCT04397653` - Evolocumab Plus Ezetimibe in High Risk Haemodialized Statin Intolerant Patients	Phase 4
Active, not recruiting	`NCT03938285` - Effect of Hemodiafiltration Plus MCOs on Uremic Toxins Removal	N/A
Completed	`NCT03525223` - Modulation of Tissue Sodium in Hemodialysis Patients	N/A
Completed	`NCT01324128` - A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients	Phase 3
Not yet recruiting	`NCT04600193` - a Randomized Controlled Trial of the Intake of Organic and Inorganic Phosphate in Peritoneal Dialysis Patients	N/A
Not yet recruiting	`NCT06225544` - Lumasiran in Hyperoxalaemic Patients on Haemodialysis	Phase 2
Recruiting	`NCT05209880` - Advance Care Planning in the Emergency Department	N/A
Enrolling by invitation	`NCT05086185` - Effect of Viscous Fiber on Postprandial Kalemic Response in Hemodialysis Patients